Thyroid Nodules: Understanding How Doctors Distinguish Benign From Malignant — A Complete Patient Guide

Table of Contents

• Key Points
• Background: Why This Research Matters
• What Are Thyroid Nodules?
• Evaluating a Thyroid Nodule: History and Physical Exam
• Laboratory Tests: The Role of TSH and Other Blood Markers
• Radionuclide Imaging: When Is It Used?
• Ultrasonography: The Imaging Gold Standard
• Fine-Needle Aspiration: The Definitive Diagnostic Tool
• Management: What Happens After the Results?
• Incidentalomas: Nodules Found by Chance
• Thyroid Nodules in Children
• Thyroid Nodules During Pregnancy
• Clinical Implications for Patients
• Limitations of This Article
• Frequently Asked Questions
• Source Information

Key Points

• Most thyroid nodules are benign; only 7–15% are malignant, so generalized panic is not warranted.
• Evaluation follows a clear pathway: TSH blood test, then ultrasound, then FNA if ultrasound features indicate risk.
• Not every nodule needs biopsy: size thresholds depend on ultrasound risk pattern, ranging from ≥1 cm to ≥2 cm.
• Incidental thyroid nodules found on CT, MRI, or PET require ultrasound assessment to determine malignancy risk.
• Children with thyroid nodules have higher malignancy risk (26% in one large review), so more aggressive management is appropriate.

Background: Why This Research Matters

The widespread use of medical imaging — including CT scans, MRIs, and ultrasounds — has led to a dramatic increase in the detection of thyroid nodules. This is both good news and a challenge.

The challenge for doctors is that while the majority of nodules are benign (non-cancerous), the risk of malignancy (cancer) in an adult ranges from 7% to 15%. That means for every 100 adults with a thyroid nodule, roughly 7 to 15 will have cancer. General practitioners must therefore be skilled at evaluating these nodules and referring patients to specialists when appropriate.

This guide, published in the Australian Journal of General Practice in November 2018, was written to bring GPs up to date on evidence-based management of thyroid nodules, with particular focus on neoplastic (tumor-forming) nodules and significant changes introduced in the 2015 American Thyroid Association (ATA) guidelines.

The stakes are high on both sides. Missing a cancer diagnosis can lead to significant harm, but over-investigating the many benign nodules creates an enormous economic burden on the healthcare system. The goal is a balanced, standardized approach.

What Are Thyroid Nodules?

Thyroid nodules are discrete lesions (distinct abnormal growths) present within the thyroid gland — the butterfly-shaped gland in the front of your neck that regulates metabolism. They are radiologically distinct from the adjacent normal thyroid tissue.

Here is how common they are:

• Palpable (feelable by hand) in 4–7% of the population
• Detected using ultrasonography in up to 67% of adults
• Risk of malignancy: approximately 7–15%

Thyroid nodules come in several types, classified by their cellular makeup:

*Thyroid cysts are nearly uniformly benign.

This classification matters because it drives the next steps in evaluation and treatment.

Evaluating a Thyroid Nodule: History and Physical Exam

Thyroid nodules can present in several ways. Most are simply a lump in the neck noticed by either the patient or the doctor, without any associated symptoms. Many others are found incidentally on imaging tests ordered for unrelated conditions, such as a CT scan of the chest or a carotid ultrasound.

Larger nodules can cause compressive symptoms, including:

• Dyspnoea (shortness of breath)
• Globus (a sensation of a lump in the throat)
• Dysphagia (difficulty swallowing)

Any symptom suggestive of invasion of nearby structures — especially dysphonia (hoarseness or voice changes) or dysphagia — should raise suspicion for an underlying malignancy and prompt urgent evaluation.

Key History Points

A thorough history is vital in formulating a complete risk assessment. The single most important historical factor is a history of childhood head and neck irradiation (radiation therapy), which significantly increases the likelihood that a thyroid nodule is malignant.

While the majority of thyroid malignancies are sporadic (occurring by chance), a number of familial (inherited) conditions can predispose a person to thyroid cancer, including:

• Multiple endocrine neoplasia type 2 (MEN2) — an inherited syndrome associated with medullary thyroid cancer
• Familial nonmedullary thyroid cancer (FNMTC) — affects two or more first-degree relatives and can occur in isolation or as part of a syndrome

FNMTC can also be part of broader genetic syndromes, including familial adenomatous polyposis (FAP), Cowden's syndrome, Gardner's syndrome, and Carney's complex type 1.

Physical Examination

Clinical examination should involve inspection and palpation (feeling) of the thyroid gland and examination of the cervical lymph nodes in the neck. The nodule itself should be assessed for three features:

1. Size
2. Consistency (how firm or soft it feels)
3. Mobility (whether it moves freely)

When the patient swallows, the thyroid and any nodule should move in an upward direction — this is a normal finding. The presence of a firm, fixed (immobile) nodule or ipsilateral cervical lymphadenopathy (enlarged lymph nodes on the same side of the neck) are late features suggestive of malignancy and should not delay further assessment.

Laboratory Tests: The Role of TSH and Other Blood Markers

A thyroid-stimulating hormone (TSH) serum level should be obtained in all patients suspected of having a thyroid nodule on examination, or in whom one was incidentally discovered. TSH is the pituitary hormone that tells the thyroid to produce thyroid hormones — measuring it is the first screening blood test.

Here is what the results mean:

• Normal TSH (euthyroid): This is the case for the majority of patients. The nodule is likely not producing excess hormone.
• Suppressed TSH: This indicates a hyperfunctioning nodule — a nodule that is producing thyroid hormone on its own. If confirmed, such a nodule has an exceedingly small risk of malignancy (less than 1%).

Patients with suppressed TSH levels are best managed by an endocrinologist (a hormone specialist) for further evaluation, which typically includes a radionuclide scan.

Tests That Should NOT Be Routinely Ordered

• Serum thyroglobulin levels: These are neither sensitive nor specific for the detection of thyroid cancer and should not be ordered in the initial evaluation of thyroid nodules. (Thyroglobulin is a protein made by the thyroid, but blood levels do not reliably distinguish benign from malignant nodules.)
• Serum calcitonin levels: These are expensive to obtain and should only be requested when a medullary thyroid carcinoma is specifically suspected, since calcitonin is the tumor marker for this rare cancer type.

Radionuclide Imaging: When Is It Used?

The 2015 ATA guidelines recommend that only patients with a TSH level below the normal range should undergo a radionuclide test. This test establishes whether there is an overactive gland or a hyperfunctioning ("hot") nodule that is producing excess thyroid hormone.

Two types of radionuclide tracers are available:

1. Iodine-123 (¹²³I) — the recommended radionuclide in the ATA guidelines
2. Technetium-99m pertechnetate (⁹⁹ᵐTc) — more accessible, easier, faster, and less expensive to perform in Australia

A study directly comparing the results of these two types of scintiscans (nuclear medicine imaging) showed a high degree of correlation, particularly when differentiating between "hot" (hyperfunctioning) and "cold" (non-functioning) nodules. In general practice, radionuclide scans should not be routinely ordered to evaluate thyroid nodules unless indicated by a low TSH result, and ⁹⁹ᵐTc should be the imaging modality of choice when a scan is needed.

Ultrasonography: The Imaging Gold Standard

Ultrasonography (ultrasound) is the imaging modality of choice for thyroid nodules. High-resolution ultrasound machines can detect nodules as small as 1–3 mm, with a sensitivity of approximately 95% — meaning it catches 95 out of 100 nodules present.

Who should get an ultrasound?

• All patients suspected of having a thyroid nodule or nodular goitre (an enlarged thyroid with nodules)
• All patients in whom a nodule has been incidentally detected on another imaging modality (CT, MRI, PET)

It is recommended that the thyroid nodule is not imaged in isolation — the entire thyroid gland and neck should be examined so that other nodules and lymph nodes are assessed simultaneously.

Ultrasound Risk Stratification: The 2015 ATA System

The ultrasound assessment provides valuable information regarding the size and sonographic (ultrasound) features of nodules, which form the basis for risk stratification and guidance on whether fine-needle aspiration (FNA) is needed.

The 2015 ATA guidelines categorize thyroid nodules into five groups based on their sonographic pattern. Each category carries an estimated malignancy risk and a specific FNA recommendation:

Because ultrasound reports do not yet consistently contain this formal risk stratification, GPs should be aware that the sonographic features with the highest specificity for thyroid cancer include:

• Microcalcifications (tiny calcium deposits visible on ultrasound)
• Irregular margins (nodule borders that are not smooth)
• Taller-than-wide shape (greater anteroposterior diameter than transverse diameter on an axial recumbent image)

If it is unclear from the ultrasound or the report whether an FNA is required, the patient should be referred to a specialist who manages thyroid nodules — commonly an endocrinologist.

Fine-Needle Aspiration: The Definitive Diagnostic Tool

Fine-needle aspiration (FNA) is a procedure in which a thin needle is inserted into the nodule (usually guided by ultrasound) to collect cells for microscopic examination. It is a valuable and safe tool that has dramatically reduced the need for unnecessary thyroidectomies (surgical removal of the thyroid).

When considering only technically satisfactory specimens, the diagnostic accuracy of FNA when performed by an experienced operator is approximately 95%, although this figure depends on how each cytology (cell) category is used in the calculation.

The decision to perform FNA depends on the sonographic pattern and the size of the nodule, as detailed in Table 2 above. The key thresholds are:

• Nodules with benign ultrasound features: no FNA needed
• Very low suspicion nodules ≥2 cm: consider FNA
• Low suspicion nodules ≥1.5 cm: FNA recommended
• Intermediate suspicion nodules ≥1 cm: FNA recommended
• High suspicion nodules ≥1 cm: FNA recommended

The Bethesda Classification System

A major update is that all cytology results should now be reported using the Bethesda system for classification of thyroid nodules, which aligns with the Thy classification system adopted by the Royal College of Pathologists in the UK.

The Bethesda system categorizes FNA results into six diagnostic categories, each with an associated malignancy risk and a recommended management plan:

• Bethesda I — Non-diagnostic/unsatisfactory: Repeat FNA or refer for further assessment
• Bethesda II — Benign: Malignancy risk ~0–3%; monitor with clinical follow-up
• Bethesda III — Atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS): Malignancy risk ~5–15%; refer to endocrinologist
• Bethesda IV — Follicular neoplasm/suspicious for follicular neoplasm (FN/SFN): Malignancy risk ~15–30%; refer to endocrinologist
• Bethesda V — Suspicious for malignancy: Malignancy risk ~60–75%; refer to high-volume thyroid surgeon
• Bethesda VI — Malignant: Malignancy risk ~97–99%; refer to high-volume thyroid surgeon

Management: What Happens After the Results?

The primary goal of the GP is to differentiate between a benign and a malignant nodule. Cytology (the FNA cell analysis) plays a key part in determining the most appropriate management and follow-up.

Benign Cytology

The majority of thyroid nodules encountered in general practice will have benign cytology. These can be monitored with a repeat ultrasound scan at a time interval determined by the sonographic features rather than treated surgically.

Non-Diagnostic Results

A non-diagnostic or unsatisfactory FNA test should have a repeat ultrasound-guided FNA or be referred on for further assessment.

Indeterminate or Suspicious Results

With the exception of benign cytology, all other results should be referred to an endocrinologist or thyroid surgeon for further assessment. Management of indeterminate cytology can be complex. Many endocrinologists are now experienced in interpreting and performing thyroid ultrasonography and FNA and can offer expertise in interpreting indeterminate results.

Any malignancy or suspected malignancy should be referred directly to a high-volume thyroid surgeon — that is, a surgeon who performs a large number of thyroid operations and therefore has better outcomes.

Follow-Up Timing for Nodules That Don't Undergo FNA

A significant proportion of thyroid nodules do not meet FNA criteria (because they are small or have reassuring ultrasound features). For these, ultrasound features guide follow-up:

• Highly suspicious nodules: repeat ultrasonography within 6–12 months
• Low-risk and intermediate-risk nodules: repeat ultrasonography within 12–24 months
• Very low risk nodules <1 cm: these have been shown to grow very little over five years and do not require routine ultrasonographic follow-up

Incidentalomas: Nodules Found by Chance

An incidentaloma is a non-palpable (cannot be felt), asymptomatic thyroid nodule detected via imaging performed for other reasons. Importantly, an incidentaloma has the same malignancy risk as a palpable nodule — so it cannot be dismissed simply because it was found by accident.

Key points about incidentalomas:

• CT and MRI scans cannot give precise structural details of the thyroid. Nodules detected using these techniques should be assessed further with ultrasonography.
• A large proportion of incidentalomas will be under 1 cm. It is important they are managed according to the guidelines to avoid over-investigation and unnecessary procedures.
• Approximately 1–2% of FDG-PET scans (a type of functional imaging used mainly in cancer staging) show focal thyroid uptake.
• A recent meta-analysis showed that 35% of those focal PET-positive nodules were malignant — a strikingly high rate.

Because of this increased risk of malignancy, the new recommendation is for patients to undergo ultrasound-based FNA for all focal nodules >1 cm detected on FDG-PET. Nodules smaller than 1 cm that do not meet FNA criteria should be monitored.

Thyroid Nodules in Children

Thyroid nodules are less common in children, but when they do occur, the risk of cancer is much higher than in adults.

• Incidence of palpable paediatric thyroid nodules: approximately 1.8–5.1% with the use of ultrasonography.
• In a review of 1,134 children, the overall malignancy rate was 26% — compared with only 5–10% in adults.

The ATA guidelines suggest paediatric nodules should be evaluated in a similar manner to adult nodules, with some important exceptions:

1. FNA size thresholds differ: Because children and their thyroid glands are proportionally smaller, FNA should be based on clinical context and sonographic features rather than the absolute size of the nodule.
2. Indeterminate cytology is treated more aggressively: In cases of indeterminate cytology, because of the increased risk of malignancy, referral to a thyroid surgeon for hemithyroidectomy (removal of half the thyroid) is recommended over a repeated FNA.

This reflects the principle that "children are not small adults" — their disease behaves differently and requires a more proactive surgical approach.

Thyroid Nodules During Pregnancy

Nodules detected during pregnancy should be assessed on the basis of serum TSH levels:

• If the TSH level is normal or elevated, FNA should be performed.
• The good news: Thyroid cancer does not behave more aggressively during pregnancy, and age-matched non-pregnant women have a similarly excellent prognosis.

Patients with nodules detected during pregnancy should be referred to a thyroid surgeon for discussion regarding delaying surgery or timing surgery to minimize fetal and patient risks. In many cases, surgery can be safely postponed until after delivery.

Clinical Implications for Patients

So, what does all of this mean for you as a patient? Here are the key takeaways:

1. Most nodules are benign — only 7–15% are malignant, so try not to panic when a nodule is found.
2. Your doctor will follow a clear, evidence-based pathway: blood test for TSH first, then ultrasound, then FNA if the ultrasound features warrant it.
3. Not every nodule needs a biopsy — small nodules with reassuring ultrasound features can be safely monitored. The ultrasound pattern determines the threshold for FNA (size cutoffs range from ≥1 cm for high-risk patterns to ≥2 cm for very low-risk patterns).
4. Radionuclide scans are reserved for patients with low TSH — they are not part of routine evaluation for everyone.
5. If you have a concerning result, you will be referred quickly — to an endocrinologist for indeterminate results, and directly to a high-volume thyroid surgeon for confirmed or suspected malignancy.
6. If your nodule was found by accident on a CT or MRI, you need a follow-up ultrasound to properly characterize it.
7. If you had childhood radiation to the head or neck, tell your doctor — this significantly raises your risk and may change management.
8. Children with nodules are a special case — the cancer risk is much higher (26% in one large review), so a more aggressive approach is justified.
9. Pregnancy is not a reason to delay evaluation — but surgery can often be safely postponed, and outcomes are excellent.

Limitations of This Article

This is a clinical review article, not a new research study. As such, it summarizes existing evidence and guidelines rather than presenting new patient data. Some limitations to be aware of:

• The malignancy risk estimates (e.g., 7–15% overall, 26% in children) come from various studies with different populations and time periods, so individual risk may vary.
• The 95% diagnostic accuracy of FNA depends heavily on the experience of the operator and the cytology category used in the calculation.
• The article reflects the 2015 ATA guidelines; newer updates may have refined some recommendations since publication.
• This article is written for Australian general practice; availability of specific tests (such as technetium-99m scans) may differ in other countries.
• Individual patient decisions should always be made in consultation with your own doctor, who has access to your full medical history, imaging, and test results.

Frequently Asked Questions

What is a thyroid nodule, and how common are they?

Thyroid nodules are distinct abnormal growths inside the thyroid gland, a butterfly-shaped gland in your neck. They are very common: found in up to 67% of adults on ultrasound and felt by hand in 4–7%. While most nodules are benign, about 7–15% are malignant, meaning they contain cancer.

How do doctors tell if a thyroid nodule is benign or malignant?

Doctors follow a standard pathway. First, they test your blood for thyroid-stimulating hormone (TSH). Next, you get an ultrasound to examine the nodule’s size and features. If ultrasound features suggest risk, a fine-needle aspiration (FNA) is done to collect cells. Most nodules are benign, and only 7–15% are malignant.

Do all thyroid nodules need a biopsy?

No. The ultrasound pattern determines whether FNA is needed. Benign-looking nodules may need no biopsy. For very low suspicion nodules, FNA is considered if they are 2 cm or larger. Low suspicion nodules need FNA at 1.5 cm or larger, while intermediate and high suspicion nodules need FNA at 1 cm or larger.

What does a low TSH level mean for my thyroid nodule?

A low TSH suggests your nodule may be hyperfunctioning, meaning it produces thyroid hormone on its own. In this case, the risk of cancer is very small, less than 1%. Your doctor will likely refer you to an endocrinologist and may order a radionuclide scan to confirm the nodule is overactive.

What is fine-needle aspiration (FNA) for a thyroid nodule?

FNA is a safe procedure where a thin needle is inserted into the nodule, usually guided by ultrasound, to collect cells for examination. When done by an experienced operator and with satisfactory samples, its diagnostic accuracy is about 95%. It helps distinguish benign from malignant nodules and reduces unnecessary surgeries.

My child has a thyroid nodule. Is the risk of cancer higher than in adults?

Yes. Although thyroid nodules are less common in children, when they occur, the cancer risk is higher: one review of 1,134 children found a 26% malignancy rate, compared with 5–10% in adults. Therefore, children are managed more aggressively, and size thresholds for FNA may differ.

My thyroid nodule biopsy came back as indeterminate or suspicious — should I get a second opinion?

Most thyroid nodules are benign, but 7–15% are malignant. If your biopsy is indeterminate or suspicious, the recommended next step varies: benign results can be monitored, while atypical (Bethesda III), follicular (Bethesda IV), suspicious, or malignant results are usually referred to an endocrinologist or high-volume thyroid surgeon. Because management of indeterminate cytology is complex, a second opinion can help you confirm whether surgery is truly necessary or whether watchful monitoring is safe. Reviewing your ultrasound images and biopsy slides by an independent expert may clarify your risk. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: RACGP - Differentiating between benign and malignant thyroid nodules

Authors: Stuart Bailey, Benjamin Wallwork

Publication: Australian Journal of General Practice (AJGP), Volume 47, Issue 11, November 2018

DOI: 10.31128/AJGP-03-18-4518

Publisher: Royal Australian College of General Practitioners (RACGP)

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your healthcare provider. Always discuss your specific situation with your doctor.